Novartis Rejiggers Pharma To Favor Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss pharma changes the leadership structure of its pharmaceutical division in an effort to emphasize oncology; AstraZeneca's Paul Hudson takes over the non-oncology pharma group as David Epstein leaves the company.